The OncLive Biosimilars condition center page is a comprehensive resource for clinical news and expert insights on currently available and investigational biosimilars for reference drugs such as trastuzumab, rituximab, bevacizumab, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates with biosimilars and ongoing research with these types of agents.
April 29th 2024
The FDA has approved trastuzumab-strf for HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or GEJ adenocarcinoma.
November 28th 2023
September 25th 2023
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Go To PER in Chicago
May 31, 2024 - June 2, 2024
Register Now!
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target
View More
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
7th Annual Live Medical Crossfire®: Hematologic Malignancies
View More
Cancer Summaries and Commentaries™: Clinical Updates in RCC from Chicago
View More
Community Practice Connections™: What the Community Needs to Know to Apply RLT in PSMA-Positive mCRPC in Context with Current Treatment Paradigms
View More
Community Practice Connections™: Integrating BTK Inhibitors Into the CLL/SLL and MCL Treatment Paradigm
View More
Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC
View More
2024 International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Regulatory Decisions, New Data Propel Progress With Biosimilars in Oncology
September 21st 2019The uptick of biosimilars has led to a surge of new data and regulatory decisions in recent years, with a focus on similarity between biosimilars and their reference products while reducing healthcare costs. This week, data on subcutaneous formulations of one biosimilar and long-term experience with another were provided, as well as an authorization of a trastuzumab (Herceptin) biosimilar in Canada.
Dr. Lyman on Rituximab Biosimilars in Non-Hodgkin Lymphoma
September 19th 2019Gary H. Lyman, MD, MPH, senior lead, Health Care Quality and Policy, Hutchinson Institute for Cancer Outcomes Research, member, Cancer Prevention Program, Public Health Services Division, and member, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the use of rituximab (Rituxan) biosimilars in the treatment of patients with non-Hodgkin lymphoma (NHL).
Lyman Shares Blueprint for Boosting Biosimilar Uptake in Oncology
September 16th 2019Gary H. Lyman, MD, MPH, discusses the current parameters used to develop a biosimilar, the impact these products have had in the treatment and supportive care settings, and ongoing initiatives to address remaining challenges.
Dr. Lyman on Educational Initiatives Regarding the Use of Biosimilars in Oncology
September 12th 2019Gary H. Lyman, MD, MPH, senior lead, Health Care Quality and Policy, Hutchinson Institute for Cancer Outcomes Research, member, Cancer Prevention Program, Public Health Services Division, and member, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses educational initiatives regarding the use of biosimilars in oncology.
Dr. Hershman on the Equivalency of Biosimilars and Biologics
September 6th 2019Dawn L. Hershman, MD, MS, professor of Medicine and Epidemiology, Columbia University Medical Center, leader of the breast cancer program at NewYork-Presbyterian/Columbia University Irving Medical Center, discusses the equivalency of biosimilars and biologics.
Dr. Bardia Discusses the Skepticism Regarding Biosimilars in Oncology
August 28th 2019Aditya Bardia, MD, MPH, director of Precision Medicine at the Center for Breast Cancer, Massachusetts General Hospital Cancer Center, and assistant professor of medicine, Harvard Medical School, discusses the skepticism regarding biosimilars in oncology.
Dr. Domchek on Potential Benefits of Biosimilars in Oncology
August 28th 2019Susan Domchek, MD, director, MacDonald Women’s Cancer Risk Evaluation Center, executive director, the Basser Center for BRCA, and Basser Professor in Oncology, at Penn Medicine, discusses the potential benefits of biosimilars in oncology.
Dr. Litton Discusses the Potential Advantage of Using Biosimilars in Oncology
August 28th 2019Jennifer K. Litton, MD, associate professor in the Department of Breast Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses the potential advantage of using biosimilars in oncology.
Dr. Welslau on Acceptance of Rituximab Biosimilar in DLBCL
August 28th 2019Manfred Welslau, MD, Internal Medicine, Hematology and Oncology, Onkologie Aschaffenburg, discusses the growing acceptance of a rituximab (Rituxan) biosimilar in the treatment of patients with diffuse large B-cell lymphoma, following favorable results from a safety analysis of the REFLECT study.
Dr. Martin on Provider Confidence With Biosimilars in Oncology
August 23rd 2019Miguel Martín, MD, PhD, professor of medicine at the Complutense University, and head of the Medical Oncology Service at the Hospital General Universitario Gregorio Marañon in Madrid, Spain, discusses provider confidence with biosimilars in oncology.
Dr. Hurvitz on the Potential Global Impact of Biosimilars in Breast Cancer
August 23rd 2019Sara Hurvitz, MD, associate professor, David Geffen School of Medicine, UCLA; medical director, Jonsson Comprehensive Cancer Center Clinical Research Unit; co-director, Santa Monica-UCLA Outpatient Oncology Practices; and director, Breast Cancer Clinical Trials Program, UCLA, discusses the potential global impact of biosimilars in breast cancer.